Germany spends much more on health – but Singapore achieves better results

Germany's health problem: High costs, but too little measurable benefit

Germany invests more in healthcare than almost any other country – but high spending alone doesn't guarantee better results. Singapore has a higher life expectancy and spends significantly less on healthcare relative to its economic output. This comparison raises a crucial question: How can we achieve better health with the resources we have?

The answer, however, is not simply to ask patients to pay more or to adopt the Singaporean model unchanged. Singapore combines personal savings with insurance coverage, government subsidies, and financial support for those who need it. The crucial factor is therefore not a single element, but the interplay of financing, provision, and governance.

For Germany, the question is therefore less about whether the healthcare system should receive more or less funding. More important is whether the resources allocated demonstrably lead to better treatment outcomes, reliable access, and effective prevention. The comparison with Singapore does not provide a simple blueprint, but it does offer important insights into how responsibility, solidarity, and efficiency could be better combined.

Germany and Singapore in a health comparison: Why more money doesn't automatically lead to better health

Expensive healthcare, poorly managed: Germany's healthcare problem cannot be solved simply by higher premiums

Germany spends a significant portion of its economic output on healthcare. Singapore achieves a higher life expectancy with a considerably lower expenditure. This contrast raises a central question in health policy: How much health is actually generated by each additional euro spent?

The obvious answer, that Singapore's success is primarily based on greater personal responsibility, falls short. The city-state combines mandatory health savings, universal basic insurance to mitigate high treatment costs, out-of-pocket expenses, and government support. The model is neither a purely market-based system nor a system where everyone bears their own risks. Its unique feature lies rather in the coordinated combination of different financing and regulatory instruments.

For Germany, therefore, simply adopting the Singaporean system unchanged is not crucial. What is interesting is which of its principles could contribute to better coordinating care, making costs more transparent, and preventing avoidable illnesses. The economically viable perspective is that Germany needs greater accountability for outcomes at all levels. This includes insured individuals as well as health insurance funds, medical institutions, policymakers, and public administration.

The spending gap is large, but the comparison needs a uniform benchmark

Health expenditure in Germany amounted to €538.2 billion in 2024. This corresponded to €6,444 per capita and 12.4 percent of the gross domestic product. Compared to 2023, expenditure increased by €37.9 billion, or 7.6 percent. Adjusted for inflation, the increase was 3.9 percent. This meant that the rise was not solely due to inflation: even after accounting for price developments, more resources were allocated to healthcare.

Singapore's share of healthcare expenditure in economic output is significantly lower. However, the frequently cited figure of around 5.5 percent should not be treated as a fixed value. This rate fluctuates depending on the reference year, exceptional healthcare expenditures, and economic performance. A 2026 healthcare policy review described Singapore's total healthcare expenditure ratio as less than five percent. It also emphasized that approximately half of the national healthcare bill is financed through tax revenues and government subsidies.

This classification alone changes the interpretation. Singapore is not inexpensive because the state plays a minimal role in healthcare. Rather, it finances and controls significant parts of the system, while other costs are covered through mandatory savings, insurance, and direct payments.

The comparison of approximately US$4,500 per capita in Singapore and US$9,000 in Germany is also insufficiently reliable without further information. It must be clarified whether nominal dollar figures or purchasing power parity (PPP) adjusted international dollar figures are meant, which year is being considered, and which expenditure components are included. The OECD estimated Germany's PPP-adjusted healthcare expenditure for 2024 at approximately US$9,300 to US$10,000 per capita within a group of countries. These figures are not directly comparable to a nominal dollar amount from another statistical source.

The statement that Germany spends roughly twice as much therefore describes a plausible order of magnitude of the difference, but not a universally valid indicator. A precise efficiency analysis must compare expenditures using the same methodology, for the same year, and with the most uniform definitions possible. Otherwise, seemingly exact relationships emerge, but their significance is less than the figures suggest.

Singapore's lead in life expectancy is real, but it does not yet explain its causes

A significant difference is evident in life expectancy. In Singapore, it was 83.5 years in 2024. Men statistically reached 81.2 years, and women 85.6 years. In Germany, life expectancy in the same year was 78.9 years for men and 83.5 years for women. This gender-specific comparison thus shows that Singapore has a lead of 2.3 years for men and 2.1 years for women.

This difference is significant from a health policy perspective. It justifies the question of why a country with high health expenditures is not among those with the best results. However, it does not prove that a single financing instrument is responsible for the gap.

Life expectancy reflects the interplay of numerous factors. These include medical care, income levels, education, nutrition, exercise, working conditions, environmental pollution, and individual risks. A healthcare system addresses the consequences of these influences but cannot completely compensate for them. Therefore, directly comparing expenditures and life expectancy leaves open the question of what portion of the result is actually attributable to healthcare provision.

Infant mortality requires similarly careful consideration. The figure of 1.7 deaths per 1,000 live births occasionally cited for Singapore cannot be readily attributed to the year 2024. Official statistics show a value of 2.2 for 2023, 2.3 for 2024, and 2.0 for 2025. These fluctuations alone demonstrate why a single annual figure should not be overinterpreted.

The comparison of approximately 1.7 for Singapore and 3.5 for Germany cannot therefore be considered a current, methodologically sound comparison without further scrutiny. A reliable assessment would require identical reference years, uniform definitions, and ideally, multi-year averages. This is not a statistical inconsequentiality: the rarer an event, the more even small absolute changes can influence the published rate.

The objective conclusion remains clear: Singapore achieves better results on a key health indicator with lower overall economic expenditure intensity. However, the mechanisms responsible for this and which of them would be transferable require further investigation.

Why international rankings do not replace actual analysis

The claim that Singapore regularly ranks first in health rankings, while Germany predominantly ranks between tenth and twentieth, sounds conclusive. However, without specifying the respective rankings, it is not sufficiently meaningful.

One ranking might place particular emphasis on low costs and high life expectancy. Another might focus on financial security, access to specialists, care for the chronically ill, waiting times, or patient satisfaction. Depending on the selection and weighting of criteria, different rankings emerge. Therefore, a top ranking is no substitute for an examination of the underlying criteria.

For a system comparison, a multidimensional approach is more meaningful. Crucially, it's not just how long people live, but also how many years they spend without significant health limitations. Equally relevant are preventable deaths, the quality of treatment, access regardless of income, and the risk of being financially overwhelmed by illness.

Germany might excel in one category while exhibiting significant weaknesses in another. The same applies to Singapore. A nuanced comparison should highlight these tensions, rather than condensing all attributes into a single ranking.

From an economic perspective, the distinction between efficiency and distribution is particularly important. A system can achieve good average results with little money while simultaneously disproportionately burdening certain groups. Conversely, an expensive system can ensure broad access without using its resources effectively. A convincing reform must address both of these issues.

Singapore's success principle is the combination, not individual responsibility alone

The Singaporean financing model is characterized by the combination of government subsidies with MediSave, MediShield Life, and MediFund. These components fulfill different functions: The government reduces treatment costs through subsidies, MediSave provides earmarked individual savings, MediShield Life distributes high health risks across an insurance pool, and MediFund supports people with remaining financial difficulties.

This architecture is important because health risks vary greatly. Smaller, predictable expenses are generally easier to save for than a serious cancer diagnosis or lengthy intensive care treatment. Major risks require broad financial coverage. Conversely, people with low incomes may still need support even if savings and insurance components are in place.

The guiding principle of personal responsibility plays a recognizable role in this system. Medical services should not be completely separated from their financial consequences for patients. At the same time, state and insurance-based safeguards prevent this principle from being applied without restriction to existential health risks.

This distinguishes the actual model from the simplified notion that low healthcare costs arise primarily from patients paying more out of pocket. Singapore combines co-payments with public funding and social compensation. Those who only cover the co-payments but ignore the other components are not copying the system, but merely one of its potentially burdensome elements.

For Germany, this leads to a key lesson: financing instruments must be evaluated as a coherent system. A health account can be inadequate without insurance coverage. A deductible can be unfair without income protection. An insurance policy can finance perverse incentives without healthcare management. Quality arises from the interplay of these elements.

Personal health accounts create visibility, but not automatic cost savings

MediSave is a mandatory medical savings scheme. A portion of your income is set aside for your own healthcare expenses and certain expenses of eligible dependents. Under specified conditions, these funds can be used for hospital treatments, certain outpatient services, insurance premiums, and healthcare costs in old age, among other things. Withdrawal rules are designed to prevent the savings from being depleted prematurely.

The economic appeal lies in the connection between today's preventative measures and future needs. People see that health requires resources. At the same time, a financial reserve is created that is available for defined expenditures.

A German model could be financed by contributions from employees and employers. However, it would have to be clarified from the outset whether these contributions would be levied in addition to existing ones or diverted from existing insurance contributions. This distinction determines the actual effects.

Additional contributions would increase the burden on earned income, even if the accumulated funds were legally allocated to individual recipients. Diverting existing health insurance contributions, on the other hand, would initially draw funds from the current solidarity-based redistribution system. The medical bills of already ill insured individuals would not disappear as a result.

This is precisely where the transition problem lies. A pay-as-you-go system finances current services from current revenues. If capital is simultaneously being accumulated for future expenditures, current services still need to be paid for. Without additional funding, a gradual transition, or real spending cuts, a funding gap will emerge.

Furthermore, there is the issue of unequal savings capacity. People with high and consistent incomes can build up savings more quickly than those with low wages, longer career breaks, or early-onset illnesses. A viable model would therefore require subsidies, protective regulations, and a clearly defined core of solidarity.

Health accounts would therefore primarily be an instrument for financing and transparency. Whether they save costs for the economy as a whole depends on whether they improve medical decisions, limit administrative costs, and do not delay necessary treatments. Simply transferring a bill from the health insurance company to a personal account does not constitute an increase in efficiency.

Major health risks belong in a reliable insurance community

MediShield Life offers Singaporean citizens and permanent residents lifelong basic protection against high hospital bills and selected expensive outpatient treatments. These include, for example, dialysis and certain cancer treatments. Coverage is generally independent of age and pre-existing conditions. Benefits are based on subsidized care in public hospitals.

The system links insurance coverage with financial participation. In addition to a deductible, there are tiered out-of-pocket expenses. For higher eligible amounts, the percentage decreases from an initial ten percent to five percent and finally to three percent. At the same time, there are benefit limits. Expenses exceeding these limits can result in additional costs.

For Germany, what is new about this is not so much the existence of compulsory insurance, but rather the clear functional separation between large insured risks and limited individual financing shares. However, any reform would have to precisely define what constitutes a severe or particularly costly risk.

A narrow definition could create significant gaps. Chronic illnesses are not always characterized by a single spectacular bill. Often, consistently high overall costs arise from medications, examinations, therapies, and support needs. An insurance policy focused solely on rare major claims might not adequately cover such cases.

Therefore, insurance coverage should be based on medical need and financial capacity, not just the amount of a single bill. Furthermore, an annual maximum out-of-pocket limit must cover all relevant out-of-pocket expenses. If certain services are excluded, a formally limited out-of-pocket amount can still result in a significant actual financial burden.

The valuable lesson is not that Germany should reduce its existing protection to a narrow disaster insurance policy. It is that responsibilities, benefit commitments, and individual limits of financial burden should be structured in a clear and reliable manner.

Co-payments are a control instrument with significant side effects

Co-payments for doctor's visits, medications, and dental treatments are intended to promote a more conscious approach to healthcare. The underlying idea is understandable: if an additional service doesn't have an immediately visible price for the individual, demand can be higher than it would be if the full cost were known.

However, this logic is only partially applicable in healthcare. Patients cannot reliably assess the medical benefit of many services themselves. Those experiencing pain, shortness of breath, or unclear symptoms often don't know before an examination whether they have a harmless condition or a serious illness.

A flat fee makes no distinction between unnecessary and necessary doctor visits. It initially increases the price of both. This creates the risk that not only unhelpful services, but also sensible diagnostics and early treatment will be omitted.

The economically crucial question is therefore not whether the number of doctor visits decreases. The decisive factor is which visits are eliminated and what the consequences are. A short-term reduction in expenditure can be negated by subsequent complications, hospital stays, or lost work time.

For a reformed German approach, patient co-payments differentiated according to medical benefit would be more plausible than a blanket charge. Necessary treatments for chronic illnesses, recommended vaccinations, and clearly justified preventative care should ideally face no financial barriers. However, transparent additional costs might be more justifiable when medically equivalent but differently priced options exist.

An income-dependent annual cap would be essential. Equally important would be relief that is as automatic as possible. A protective mechanism loses its effectiveness if people with limited financial or administrative resources have to submit complicated applications and initially pay large sums upfront.

Prevention is an investment in health, but not a guaranteed savings machine

Increased prevention is among the most compelling reform goals. However, from an economic perspective, it should not be justified by the blanket promise that every preventative measure will save more money later than it costs today.

Prevention can avert diseases, delay their onset, or mitigate their progression. These effects can be medically and socially valuable, even if overall healthcare spending does not decrease. After all, a longer life expectancy also means that people may require medical services for a longer period.

The appropriate evaluation question is therefore how much health a measure generates in relation to its costs. A cost-effective intervention with significant benefits can be particularly attractive. Conversely, an expensive measure with little added benefit must be critically examined, even if it is offered under the positively connoted term "preventive care.".

Early detection also requires a nuanced approach. While it can improve treatment outcomes, it can also trigger additional tests, false alarms, and the discovery of changes that might never have caused symptoms without investigation. Prevention, therefore, requires the same objective benefit assessment as therapy.

Singapore's MediSave system allows for expenses related to certain vaccinations, examinations, and the treatment of chronic illnesses. This demonstrates that individual savings tools need not be used exclusively for acute hospital bills. They can also be integrated into a long-term healthcare strategy.

For Germany, a stronger focus on preventable disease burden would be beneficial. This includes easily understandable health information, readily accessible services, and reliable support for those already ill. The crucial factor is not the number of preventive programs, but their demonstrable effectiveness and their actual use by particularly vulnerable groups.

Bonus systems must encourage behavior without punishing illness

Bonus systems for preventative care and health-promoting behavior can raise awareness and support concrete actions. They also offer the opportunity to frame personal responsibility positively: not as a sanction for illness, but as support for health-promoting decisions.

However, the design is challenging. A bonus should be linked to actions that can be influenced, and not simply to good health. Good lab results, a low body weight, or the absence of illness are not solely the result of personal effort.

Rewarding people for already having a favorable starting position risks redistribution in favor of already privileged groups. People with chronic illnesses, disabilities, or demanding working conditions could fare worse, even though they behave particularly responsibly within their means.

More plausible would be low-threshold incentives for appropriate vaccinations, participation in medically justified programs, or reliable cooperation in an individually tailored treatment plan. However, it would also have to be considered whether such offers are actually accessible.

A bonus for regular exercise is hardly convincing if shift work, caregiving responsibilities, or a lack of accessible facilities make participation difficult. A fair design therefore takes different life situations into account and offers equivalent alternatives.

Furthermore, every bonus must justify its costs. Expenditures for rewards, data collection, auditing, and advertising can be considerable. A program should not be continued simply because it achieves high participation rates. It should demonstrate that it changes behavior, provides health benefits, and does not merely reward activities that would have been planned anyway.

Transparent pricing is only helpful if medical quality is understandable

The demand for transparent pricing and quality data is justified. Patients should be able to understand what treatment is planned, what alternatives exist, and what the potential financial consequences might be. Singapore, for example, relies on transparent billing practices, fee guidelines, and billing procedures for public institutions.

However, healthcare doesn't function like a typical market. In an acute emergency, there's no time for comparison. With complex illnesses, laypeople can only partially assess the quality of a recommendation. Even published success rates are misleading without further context.

A hospital treating particularly severe cases may show worse unadjusted results than a facility with less severely ill patients. This does not automatically imply lower treatment quality. Therefore, quality data must take differences in disease risk into account and be presented in an easily understandable way.

Prices also require context. A low price can reflect efficient organization, but it can also indicate a different scope of services. A higher price can result from additional services, more complex cases, or inefficient structures. Without clear distinctions, the comparison remains superficial.

For Germany, a combination of easily understandable patient information and professional quality evaluation would be particularly beneficial. Patients need guidance, while health insurance companies and healthcare planners require more detailed data for contract design and structural decisions.

Transparency must not become just another bureaucratic exercise in itself. New documentation requirements should only be introduced if the collected data is actually used and existing duplicate reports are eliminated. A system that is extensively measured is not necessarily a well-managed system.

Germany's reform problem doesn't begin with the behavior of patients

A debate that focuses almost exclusively on personal responsibility narrows the causes of high expenditures. Medical services are not solely demanded by patients. Their scope also depends on medical recommendations, reimbursement rules, organizational structures, and available capacity.

From an economic perspective, all parties involved respond to incentives. If an additional service is reimbursed, while avoiding an unnecessary intervention receives no comparable financial value, a tension can arise between medical benefit and economic interest. The same applies if collaboration between institutions costs time without being adequately compensated.

A sensible reform approach must therefore focus on the supply side. It would be necessary to examine which reimbursement rates support needs-based care and which primarily encourage additional volume. Equally important is the question of how treatments are coordinated across different facilities.

For patients, a system with many access points can seem convenient but simultaneously confusing. Repeated examinations, unclear responsibilities, and a lack of information sharing cause stress without necessarily creating additional benefits.

A stronger coordinating role for primary care would therefore be a plausible approach. However, this should be linked to good accessibility, medical expertise, and timely referrals. Simply erecting additional barriers to access without strengthening coordinating care would merely shift the problem.

In this context, personal responsibility can mean adhering to agreed-upon care pathways and utilizing available information. Institutional responsibility, at the same time, means making these pathways understandable, accessible, and medically sound.

Government control capacity is more important than the lowest possible government spending ratio

Singapore's lower healthcare expenditure ratio does not directly imply that a lower overall government spending ratio leads to better health. The government spending ratio describes all government expenditure in relation to economic output. On its own, it says little about how effectively a particular healthcare system is organized.

It is also important to distinguish between government healthcare spending and total healthcare spending. Singapore's government healthcare spending in fiscal year 2023 amounted to approximately 17.2 billion Singapore dollars, or 2.5 percent of its gross domestic product. This figure represents only a portion of the financing and should not be directly compared to Germany's total healthcare spending of 12.4 percent.

The city-state provides substantial public funding. In public hospitals, subsidies can cover up to 80 percent of certain bills. In addition, there are income-based assistance with insurance premiums and other support measures.

Thus, the defining characteristic is not the absence of the state, but rather a specific form of state organization. The state defines rules, provides funding, limits burdens, and intervenes in cases of financial need.

For Germany, the question of reform should therefore not be whether as little government as possible would be fundamentally better. It should be which tasks can be fulfilled most effectively centrally, regionally, competitively, or through solidarity.

A lower expenditure ratio would be a success if it resulted from better care, prevented illnesses, and more efficient processes. It would not be a success if costs were merely shifted to households or if necessary services became more difficult to access.

The city-state and the rural state face different organizational challenges

Singapore and Germany differ in their spatial and institutional structures. These differences limit the direct transferability of individual solutions.

In a densely populated city-state, supply routes can be organized differently than in a rural country with large cities, smaller towns, and sparsely populated regions. The concentration of specialized services can have different consequences for accessibility and transport under such conditions.

This creates a conflict of objectives for Germany. A greater consolidation of complex treatments can offer organizational advantages. At the same time, local care for everyday and time-critical needs must be maintained. Efficiency, therefore, does not necessarily mean imposing the same structure everywhere.

Political responsibilities also influence reforms. Where financing, planning, oversight, and service delivery are distributed across different institutions, changes must be coordinated among multiple actors. An instrument that can be implemented quickly in a more centralized system requires a different governance structure elsewhere.

This is not an argument against reforms. It is an argument against the idea that a foreign model can be transferred simply by introducing individual terms. A health account or a new co-payment does not automatically change the entire healthcare system.

A more successful approach would be functional transfer: What problem does an instrument solve in Singapore? Does the same problem exist in Germany? Which existing institutions could take on this function? What side effects would arise under German conditions? Only these questions transform an international model into a viable reform approach.

Singapore, too, must cope with rising costs and an aging population

Singapore's results to date do not mean that its model is permanently protected against increased spending. Its health policy explicitly cites the aging population, medical advances, and rising healthcare costs as drivers of future burdens.

According to the 2026 health policy assessment, the public health budget is projected to increase from approximately 2.7 percent of gross domestic product to around 3.5 percent by 2030. This development demonstrates that even a comparatively low-spending system requires additional public funding.

This puts into perspective the idea that personal responsibility can resolve long-term financial pressures. Individual saving can shift resources over time. However, it does not automatically prevent more people from needing medical and nursing care over extended periods.

Furthermore, employees must be recruited, trained, and retained. Medical care cannot be improved solely through financing rules. It requires real capacity, competent staff, and an organization that utilizes their working time effectively.

The financial burden on households also remains a significant factor. For the lowest-income 10 percent of resident households with earned income, Singapore reported average direct healthcare expenditure of six percent of household income, based on the 2023 Household Survey. This figure already included subsidies, insurance benefits, and MediSave, but not additional assistance from MediFund or charitable organizations.

This figure is not a complete judgment on social security. However, it makes clear that good average health indicators do not replace the assessment of individual burdens. Even a successful system must continuously monitor who is contributing to its financing and which groups require special support.

The economic significance extends far beyond health insurance contributions

Healthcare expenditures are simultaneously costs, income, and investments. They burden contributors, taxpayers, and private households. At the same time, they finance employment, medical infrastructure, and services that enable quality of life and economic participation.

A purely fiscal perspective would therefore be too narrow. While foregoing effective treatment may reduce expenditures in the short term, it can simultaneously impair employability, independence, and social participation. The resulting costs may then arise in other areas.

Conversely, not every additional healthcare expenditure is automatically economically beneficial. Resources spent on services of little help are no longer available for other tasks. These include education, infrastructure, care, and effective prevention. These missed opportunities represent the true opportunity costs.

The scale of German healthcare spending illustrates the magnitude of the issue. Based on €538.2 billion in healthcare expenditure in 2024, a calculated efficiency improvement of one percent would correspond to approximately €5.4 billion. This is explicitly not a proven short-term savings opportunity, but rather an indication of the magnitude that illustrates the impact of small percentage changes.

For the economy, it would be particularly valuable if greater efficiency in healthcare provision limited contribution pressure while simultaneously improving the health of the working population. Simply shifting employer contributions to private payments is insufficient to achieve this. From a macroeconomic perspective, a bill remains a burden, regardless of the financing channel through which it is paid.

The relevant productivity gain only arises when more medical benefit is achieved with the same resources, or when the same benefit is achieved with less resource input.

A viable reform combines solidarity with verifiable responsibility

The comparison does not provide a convincing justification for a radical withdrawal of the solidarity-based health insurance system. Nor does it justify the assumption that additional financial resources would automatically solve the problems of the German system.

A sensible reform path should first improve the information and management foundations. This includes transparent quality data, understandable cost information, and better coordination between different levels of care. Without these prerequisites, patients can hardly make informed decisions, and financial incentives will have only a limited effect.

Building on this, reimbursement models should be more strongly evaluated based on whether they support medically appropriate outcomes and coordinated treatment. Reducing unnecessary services should not be left solely to patients. It is also the responsibility of healthcare providers and the institutions that finance and organize care.

Personal health accounts could be tested in clearly defined areas of application. This would require transparent transition costs, reliable protection for the chronically ill, and social compensation for people with limited savings capacity. A nationwide introduction without these clarifications would be a fiscal policy experiment with distributional effects that are difficult to predict.

Co-payments should only be used where they enable transparent decisions and do not displace necessary treatments. Bonus systems should encourage modifiable behavior rather than rewarding favorable initial health conditions. Prevention should be evaluated according to its actual benefit and should particularly reach those people whose risks are high and whose options for action are limited.

Furthermore, every major reform should be accompanied by a verifiable evaluation. This evaluation should measure not only expenditures, but also health outcomes, accessibility, individual burdens, and administrative costs. An instrument that merely shifts costs between health insurance funds, the government, and households should not be considered an efficiency success.

Germany's crucial task is to achieve more health per euro invested

Singapore demonstrates that high life expectancy does not necessarily require a healthcare spending ratio on par with Germany's. Conversely, Germany shows that extensive funding alone does not guarantee a leading position in healthcare outcomes. This comparison thus justifies considerable pressure for reform, but not a simple ideological solution.

The most compelling lesson from Singapore is the coordinated integration of individual provision, insurance, government funding, and social support. Personal responsibility is given an institutional framework there; it is not outside of public control but rather an integral part of it.

In Germany, this should create a requirement for all involved parties. Insured individuals must receive understandable information and realistic opportunities to make health-promoting decisions. Medical facilities must be measured by quality and appropriate resource allocation. Health insurance companies and policymakers must create structures in which cooperation and benefit count more than increased service volume.

The goal cannot be to spend as little as possible on healthcare. Nor should rising spending be considered a sign of a high-performing system. What matters is whether people live longer and better lives, receive necessary care in a timely manner, and remain financially protected in the event of illness.

A reform would be successful if it achieved precisely these results with less resource loss. This is the real challenge of the German-Singaporean comparison: not less solidarity, but a healthcare system that clearly assigns responsibility and demonstrably delivers better health from its considerable financial investment.